Pharmaceutical manufacturer Granules India (NSE:GRANULES, BOM:532482), has received an establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) for its Unit V facility at Jawaharlal Nehru Pharma City in Andhra Pradesh, India, according to a Friday filing to the stock exchanges.
The EIR follows an inspection conducted by the US FDA from April 8 to April 12 which classified the facility as a 'No Action Indicated' (NAI) indicating that no further regulatory action is required.
The regulator had conducted a comprehensive Pre-Approval Inspection (PAI) and current Good Manufacturing Practices (cGMP) audit, which concluded with zero Form 483 observations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.